Bharat Biotech’s Covaxin gets nod for phase 3 clinical trials

India’s indigenous COVID-19 vaccine candidate, COVAXIN, developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) has received the nod for Phase-3 clinical trials in the country. The Subject Expert Committee which functions under the drug regulator Drug Controller General of India (DCGI) has given approval for the last phase of clinical trials with certain conditions.

In the Third Phase of trials, which is proposed to begin in the first week of next month, the potential vaccine candidate will be tested on over 28 thousand people aged 18 years and above. These tests will be conducted across 10 states and 19 sites including Delhi, Mumbai, Patna and Lucknow among others.

Besides, Bharat Biotech’s COVAXIN, another indigenously developed vaccine candidate by Zydus Cadila Limited is also in Phase -2 of human clinical trials.

Click to comment

Leave a Reply

Your email address will not be published.

nine − 1 =

News is information about current events. News is provided through many different media: word of mouth, printing, postal systems, broadcasting, electronic communication, and also on the testimony of observers and witnesses to events. It is also used as a platform to manufacture opinion for the population.

Contact Info

D 601  Riddhi Sidhi CHSL
Unnant Nagar Road 2
Kamaraj Nagar, Goreagaon West
Mumbai 400062 .

Email Id: [email protected]

West Bengal

Eastern Regional Office
Indsamachar Digital Media
Siddha Gibson 1,
Gibson Lane, 1st floor, R. No. 114,
Kolkata – 700069.
West Bengal.

Office Address

251 B-Wing,First Floor,
Orchard Corporate Park, Royal Palms,
Arey Road, Goreagon East,
Mumbai – 400065.

Download Our Mobile App

IndSamachar Android App IndSamachar IOS App
To Top
WhatsApp WhatsApp us